HPV mRNA检测在宫颈癌筛查中的准确性和有效性:系统综述与Meta分析
该系统综述与Meta分析评估高危HPV mRNA检测对比DNA检测在宫颈癌初筛中的横断面准确性、纵向筛查性能及自采样与医生采样的一致性。共纳入8项横断面研究、4项纵向研究和5项自采样研究,APTIMA mRNA检测对CIN2+的相对敏感度为0.98,特异度略高(1.03),自采样敏感性较低(0.84)。作者认为APTIMA可接受用于医生采样宫颈样本的初筛,筛查间隔约5年。
要点
- APTIMA mRNA检测对CIN2+的相对敏感度为0.98(95%CI 0.95-1.01),与DNA检测相似。
- APTIMA对CIN2+的相对特异度为1.03(95%CI 1.02-1.04),略高于DNA检测。
- 自采样样本中APTIMA对CIN2+的相对敏感度为0.84(95%CI 0.74-0.96),低于医生采样。
核心结论
- APTIMA mRNA检测对CIN2+和CIN3+的横断面敏感度与DNA检测相似,特异度略高。
- 4项随访4-7年的研究显示安全性结局异质性较大;1项随访长达10年的研究显示mRNA与DNA筛查阴性后CIN3+累积检出无差异。
- 作者认为APTIMA可接受用于医生采集宫颈样本的宫颈癌初筛,筛查间隔约5年。
- 自采样样本中APTIMA的敏感度低于医生采集样本。
研究设计与样本
- 系统综述与Meta分析,检索Medline(PubMed)、Embase和CENTRAL截至2021年8月1日发表的文献。
- 纳入标准为包含三个临床问题之一比较数据的研究;采用QUADAS和ROBINS-1工具评估质量。
- 横断面准确性比较纳入8项研究(医生采样DNA对比),纵向性能比较纳入4项研究,自采样准确性评估纳入5项研究。
- 采用随机效应模型合并比例或风险比。
主要发现
- APTIMA对比DNA检测对CIN2+的相对敏感度为0.98(95%CI 0.95-1.01),相对特异度为1.03(95%CI 1.02-1.04)。
- APTIMA对比DNA检测对CIN3+的相对敏感度为0.98(95%CI 0.95-1.01)。
- 随访4-7年间APTIMA对比DNA检测对CIN3+的纵向相对敏感度在研究水平为0.91至1.05,合并分析为0.95至0.98(取决于时间点),置信区间包含或接近1。
- 基线mRNA阴性对比DNA阴性后4-10年的检出率比值在各研究间不精确且异质,但汇总比值与1无差异。
- 自采样对比医生采样,APTIMA对CIN2+的相对横断面敏感度为0.84(95%CI 0.74-0.96),相对特异度为0.96(95%CI 0.91-1.01)。
关键数值与推荐
- CIN2+:APTIMA对比DNA检测相对敏感度0.98(95%CI 0.95-1.01),相对特异度1.03(95%CI 1.02-1.04)。
- CIN3+:APTIMA对比DNA检测相对敏感度0.98(95%CI 0.95-1.01)。
- CIN3+纵向相对敏感度(随访4-7年):研究水平0.91至1.05,合并分析0.95至0.98(取决于时间点),置信区间包含或接近1。
- 自采样对比医生采样:CIN2+相对敏感度0.84(95%CI 0.74-0.96),相对特异度0.96(95%CI 0.91-1.01)。
临床怎么用
- 作者认为APTIMA可接受用于医生采集宫颈样本的宫颈癌初筛,筛查间隔约5年。
- 自采样样本中APTIMA敏感度低于医生采集样本。
- 其他mRNA检测方法因报告较少,未能纳入Meta分析评估。
局限性
- 其他mRNA检测方法的报告较少,无法纳入Meta分析评估。
- 4项随访4-7年的研究显示安全性结局异质性较大。
- 基线mRNA阴性对比DNA阴性后4-10年的检出率比值在各研究间不精确且异质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cervical cancer screening tests that identify DNA of the main causal agent, high-risk human papillomavirus (HPV) types, are more protective than cervical cytology. We systematically reviewed the literature to assess whether tests targeting high-risk HPV (hrHPV) mRNA are as accurate and effective as HPV DNA-based screening tests. METHODS: We did a systematic review to assess the cross-sectional clinical accuracy to detect cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) or 3 or worse (CIN3+) of hrHPV mRNA versus DNA testing in primary cervical cancer screening; the longitudinal clinical performance of cervical cancer screening using hrHPV mRNA versus DNA assays; and the clinical accuracy of hrHPV mRNA testing on self-collected versus clinician-collected samples. We identified relevant studies published before Aug 1, 2021, through a search of Medline (PubMed), Embase, and CENTRAL. Eligible studies had to contain comparative data addressing one of our three clinical questions. Aggregated data were extracted from selected reports or requested from study authors if necessary. QUADAS and ROBINS-1 tools were used to assess the quality of diagnostic test accuracy studies and cohort studies. To assess cross-sectional clinical accuracy of mRNA testing versus DNA testing and clinical accuracy of hrHPV mRNA testing on self-collected versus clinician collected samples, we applied meta-analytical methods for comparison of diagnostic tests. To assess the longitudinal clinical performance of cervical cancer screening using hrHPV mRNA versus DNA assays, we compared the longitudinal sensitivity of mRNA tests and validated DNA tests for CIN3+ and the relative detection of CIN3+ among women who screened negative for hrHPV mRNA or DNA (both used as measures of safety) at baseline and pooled estimates by years of follow-up. A random-effect model for pooling ratios of proportions or risks was used to summarise longitudinal performance. FINDINGS: For the hrHPV mRNA testing with APTIMA HPV Test (APTIMA), the cross-sectional accuracy could be compared with DNA assays on clinician-collected samples in eight studies; longitudinal performance was compared in four studies; and accuracy on self-samples was assessed in five studies. Few reports were retrieved for other mRNA assays, precluding their evaluation in meta-analyses. Compared with validated DNA assays, APTIMA was similarly sensitive (relative sensitivity 0·98 [95% CI 0·95-1·01]) and slightly more specific (1·03 [1·02-1·04]) for CIN2+. The relative sensitivity for CIN3+ was 0·98 (95% CI 0·95-1·01). The longitudinal relative sensitivity for CIN3+ of APTIMA compared with DNA assays assessed over 4-7 years ranged at the study level from 0·91 to 1·05 and in the pooled analysis between 0·95 and 0·98, depending on timepoint, with CIs including or close to unity. The detection rate ratios between 4 and 10 years after baseline negative mRNA versus negative DNA screening were imprecise and heterogeneous among studies, but summary ratios did not differ from unity. In self-collected samples, APTIMA was less sensitive for CIN2+ (relative cross-sectional sensitivity 0·84 [0·74-0·96]) but similarly specific (relative specificity 0·96 [0·91-1·01]) compared with clinician-collected samples. INTERPRETATION: HrHPV RNA testing with APTIMA had similar cross-sectional sensitivity for CIN2+ and CIN3+ and slightly higher specificity than DNA tests. Four studies with 4-7 years of follow-up showed heterogeneous safety outcomes. One study with up to 10 years of follow-up showed no differences in cumulative detection of CIN3+ after negative mRNA versus DNA screening. APTIMA could be accepted for primary cervical cancer screening on clinician-collected cervical samples at intervals of around 5 years. APTIMA is less sensitive on self-collected samples than clinician-collected samples. FUNDING: Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network, WHO, Haute Autorité de la Santé, European Society of Gynaecological Oncology, and the National Institute of Public Health and the Environment.
引用
- Arbyn M, Simon M, de Sanjosé S, et al. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis. Lancet Oncol. 2022. PMID: 35709810. doi:10.1016/S1470-2045(22)00294-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。